Enanta Pharmaceuticals (ENTA) on Thursday reported fiscal Q4 EPS of $0.44, compared with $1.30 a year earlier, and missing the estimate of $0.56 per share by analysts polled by Capital IQ.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Revenue for the September quarter was $51.3 million, down from $67.2 million and also falling short of the Street estimate of $56 million.

For fiscal 2020, Enanta said it expects research and development expense of $155 million to $175 million, and general and administrative expense of $27 million to $33 million.

Enanta Pharmaceuticals (ENTA) on Thursday reported fiscal Q4 EPS of $0.44, compared with $1.30 a year earlier, and missing the estimate of $0.56 per share by analysts polled by Capital IQ.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Revenue for the September quarter was $51.3 million, down from $67.2 million and also falling short of the Street estimate of $56 million.

For fiscal 2020, Enanta said it expects research and development expense of $155 million to $175 million, and general and administrative expense of $27 million to $33 million.